Welcome to our dedicated page for Align Technology news (Ticker: ALGN), a resource for investors and traders seeking the latest updates and insights on Align Technology stock.
Align Technology, Inc. (NASDAQ: ALGN) is a global medical device company best known for the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software. The ALGN news feed on Stock Titan aggregates company announcements, clinical product updates, financial disclosures, and professional education highlights directly relevant to investors and dental professionals.
Recent news shows Align focusing on digital orthodontics and restorative dentistry, with updates on innovations such as ClinCheck® Live Plan for automated Invisalign treatment planning, new features for iTero Digital Solutions, and expanded availability of Invisalign System options like mandibular advancement with occlusal blocks for Class II correction in growing patients. News items also cover Align’s participation in major dental congresses, including the Greater New York Dental Meeting, where the company showcases its Align™ Digital Platform and related tools.
Investors following ALGN news will see regular earnings announcements and outlook updates, including quarterly revenue, clear aligner volumes, imaging systems and CAD/CAM services performance, and commentary on geographic trends. SEC-related press releases, such as those tied to Form 8-K filings on financial results or leadership changes, also appear in the news flow.
Align’s communications further highlight research, education, and community programs, including its Annual Research Award Program for university-based dental research and partnerships with organizations like the Canadian Foundation for the Advancement of Orthodontics through Smiles4Canada. For users tracking ALGN, this news page offers a centralized view of product launches, clinical innovations, financial milestones, and corporate initiatives that shape the company’s role in digital dentistry.
Summary not available.
Align Technology (NASDAQ: ALGN) announced a suite of iTero Digital Solutions innovations on October 29, 2025 that expand chairside visualization, design and production workflows to boost patient engagement and treatment conversion.
Key features include the Align Oral Health Suite, Patient Gallery, simplified Oral Health Reports with QR sharing, Invisalign Outcome Simulator Pro with Smile Video (claimed to double chairside conversion for general dentistry), expanded iTero Design Suite compatibility with many 3D printers and mills, a new mock-up workflow for single-visit dentistry, and premium training and support.
New tools are globally available subject to regional regulatory approvals; Invisalign Outcome Simulator Pro availability is limited to iTero Element Plus Series and the company cites >115,000 simulations to date.
Align Technology (NASDAQ: ALGN) announced ClinCheck Live Plan, a new ClinCheck feature that automates initial Invisalign treatment plans and returns a doctor-ready 3D plan in about 15 minutes. Built on Align’s proprietary data and algorithms and experience from >21 million Invisalign patients, the system applies a doctor’s pre-configured preferences and runs quality checks after a Flex Rx submission and iTero scan. Align says ClinCheck Live Plan can shorten planning from days to minutes, enable in‑office plan approval, and improve office efficiency and patient experience. Global roll‑out is planned to begin in Q1 2026 with training resources provided.
Align Technology (NASDAQ: ALGN), a global leader in digital orthodontics and restorative dentistry, will release its Q3 2025 financial results on Wednesday, October 29, 2025, after market close at 4:00 p.m. ET. The company will host a conference call at 4:30 p.m. ET to discuss the results.
Align Technology is known for its Invisalign® System, iTero™ intraoral scanners, and exocad™ CAD/CAM software. The company serves over 286,400 doctors globally and has treated more than 20.8 million patients with the Invisalign System over 28 years, targeting a 600 million consumer market opportunity worldwide.
Align Technology (NASDAQ:ALGN) hosted its 2025 Global Faculty Meeting, bringing together over 100 Invisalign® and iTero™-trained doctor educators for comprehensive education workshops. The event, themed "Innovate. Collaborate. Educate.," focused on Align's latest innovations, clinical evidence, and best practices for treating patients of all ages.
Key highlights include the launch of a new clinical evidence webpage featuring 800+ peer-reviewed publications, expansion of the Align Global Gallery™ to over 1,500 case studies, and the continuation of the research awards program, which has provided $4 million in grants since 2010. The meeting featured presentations on patient demand, practice growth, clinical insights, and case discussions, reinforcing Align's commitment to advancing digital orthodontics and dentistry.
Align Technology (Nasdaq: ALGN) has filed a complaint with the U.S. International Trade Commission (ITC) against Angelalign Technology for alleged patent infringement related to clear aligner products. The company is seeking both an exclusion order to prevent importation of infringing products and a cease-and-desist order to stop sales of existing products in the U.S. market.
This legal action follows previous patent infringement litigation filed in August across multiple jurisdictions including the U.S. District Court, China Intermediate People's Court, and European Unified Patent Court. The complaint alleges that Angelalign's products unauthorized incorporate Align's patented technologies.
Align Technology (NASDAQ:ALGN) hosted its 2025 Invisalign® GP Summit, bringing together over 700 doctors and practice team members for a three-day educational event. The summit showcased the latest innovations in digital orthodontics, including the Invisalign® System, iTero™ scanners, and the Align™ Digital Platform.
The event featured an Innovation Hub demonstrating new technologies like the iTero Lumina™ intraoral scanner, Invisalign® Smile Video, and Align™ X-ray Insights. Align also launched the Women's Smile Collective initiative to support women in dentistry and celebrated the milestone of 20 million Invisalign® smiles transformed.
Align Technology (NASDAQ: ALGN), a leading medical device company specializing in clear aligners and digital dentistry solutions, has announced its participation in three upcoming financial conferences in September 2025.
The company's executives, including EVP Global Finance and CFO John Morici and VP Finance Shirley Stacy, will present at the 2025 Wells Fargo Healthcare Conference (Sept 3), Morgan Stanley 23rd Annual Global Healthcare Conference (Sept 9), and Baird Global Healthcare Conference (Sept 10). All presentations will be accessible via webcast through Align's Investor Relations website.
The company has treated over 20.8 million patients with its Invisalign System and serves more than 286,400 doctor customers globally.Align Technology (NASDAQ:ALGN) has initiated patent infringement lawsuits against Angelalign Technology (6699.HK) in the United States, Europe, and China. The litigation targets alleged infringement of Align's patents covering multilayer aligner materials, treatment planning, and advanced aligner features.
Align emphasizes its significant R&D investment of over $300 million annually and approximately $2 billion since 2001. The company maintains extensive global operations, including clinical treatment planning centers across multiple countries and manufacturing facilities in Mexico, Poland, and China, supporting over 20 million Invisalign® patients treated worldwide.
Align Technology (NASDAQ: ALGN) has announced plans to repurchase $200 million of its common stock through open market transactions under its $1.0 billion stock repurchase program approved in April 2025.
The buyback will be executed through a Rule 10b5-1 trading plan and is expected to be completed by January 2026, funded with cash on hand. As of June 30, 2025, Align had approximately 72.5 million shares outstanding and $901.2 million in cash and cash equivalents.
The company's management emphasizes this decision reflects confidence in their long-term strategy and market opportunity, while maintaining focus on strategic execution and disciplined investments despite macroeconomic uncertainties.